Privia Health Group, Inc. PRVA
Privia Health Group, Inc. ("Privia Health", "we", "our", or the "Company") is a technology-driven, national physician-enablement company that collaborates with physician practices, health plans, and health systems to achieve the quadruple aim of better outcomes, lower costs, improved patient experience, and happier and more engaged providers. We seek to accomplish the quadruple aim by entering markets and organizing existing physicians and non-physician clinicians into a unique practice model that combines the advantages of a partnership in a large regional medical group (each, a "Medical Group") with significant provider autonomy for the physicians (collectively, "Privia Physicians") and non-physician clinicians (collectively "Privia Clinicians" and, together with the Privia Physicians, the "Privia Providers") in our Medical Groups.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.12B | $1.74B | $1.66B | $1.36B | $966.2M | $817.1M | $786.4M | — |
| SG&A | $138.2M | $126.2M | $109.6M | $129.6M | $255.9M | $44.0M | $41.8M | — |
| Total operating expenses | $2.09B | $1.72B | $1.64B | $1.38B | $1.18B | $791.7M | $770.3M | — |
| Operating income | $34.2M | $17.0M | $20.6M | -$19.1M | -$217.4M | $25.4M | $16.1M | — |
| Interest expense | — | — | $8.4M | $542.0K | $1.1M | $1.9M | $4.0M | — |
| Pre-tax income | $43.9M | $27.9M | $29.0M | -$18.6M | -$218.5M | $23.5M | $9.2M | — |
| Income tax | $14.2M | $10.8M | $8.0M | $6.5M | $27.9M | $7.4M | $1.2M | — |
| Net income | $22.9M | $14.4M | $23.1M | -$8.6M | -$188.2M | $31.2M | $8.2M | — |
| EPS, basic | 0.19 | 0.12 | 0.20 | -0.08 | -1.83 | 0.33 | 0.09 | — |
| EPS, diluted | 0.18 | 0.11 | 0.19 | -0.08 | -1.83 | 0.33 | 0.09 | — |
| Shares, diluted (wtd. avg.) | $128.9M | $125.6M | $124.7M | $110.7M | $103.0M | $96.0M | $95.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $479.7M | $491.1M | $389.5M | $348.0M | $320.6M | $84.6M | $46.9M | $39.1M |
| Receivables | $400.9M | $316.2M | $290.8M | $189.6M | $117.4M | $99.1M | — | — |
| Total current assets | $911.0M | $834.8M | $700.8M | $552.0M | $446.7M | $190.1M | — | — |
| Property, plant and equipment | $504.0K | $1.2M | $2.3M | $3.4M | $4.5M | $4.8M | — | — |
| Goodwill | $209.8M | $141.6M | $138.7M | $126.9M | $127.9M | $118.7M | — | — |
| Other intangibles | $215.9M | $109.8M | $107.6M | $57.4M | $59.7M | $6.0M | — | — |
| Total assets | $1.37B | $1.14B | $999.9M | $792.8M | $686.4M | $329.0M | — | — |
| Accounts payable | $8.0M | $9.8M | $7.9M | $6.7M | $3.0M | $5.2M | — | — |
| Total current liabilities | $568.5M | $449.1M | $387.0M | $264.3M | $190.5M | $146.9M | — | — |
| Total liabilities | $578.4M | $452.3M | $392.5M | $273.8M | $236.2M | $185.3M | — | — |
| Retained earnings | -$156.3M | -$179.2M | -$193.6M | -$216.7M | -$208.1M | -$19.9M | — | — |
| Total equity | $737.2M | $635.2M | $607.4M | $519.0M | $450.2M | $143.7M | $107.5M | $86.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $163.4M | $109.3M | $80.8M | $47.2M | $55.1M | $38.9M | $24.4M | — |
| Depreciation and amortisation | $9.9M | $7.3M | $6.5M | $4.6M | $2.5M | $1.8M | $1.4M | — |
| Stock-based compensation | $71.1M | $56.7M | $37.1M | $67.4M | $253.5M | $484.0K | $207.0K | — |
| Capital expenditure | — | — | $113.0K | $104.0K | $547.0K | $380.0K | $5.7M | — |
| Investing cash flow | -$181.6M | -$12.0M | -$43.0M | -$104.0K | -$32.8M | -$380.0K | -$5.7M | — |
| Financing cash flow | $6.7M | $4.3M | $3.7M | -$19.7M | $213.7M | -$767.0K | -$10.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001759655-26-000010.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | $4.86B | — | 13.9% |
| WGS | GeneDx Holdings Corp. | $2.56B | — | 40.0% |
| INNV | InnovAge Holding Corp. | $1.46B | — | 11.8% |
| OMDA | Omada Health, Inc. | $1.39B | — | 53.2% |
| PNTG | Pennant Group, Inc. | $1.33B | 45.2x | 36.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.18B | 55.9x | 16.3% |
| SRTA | Strata Critical Medical, Inc. | $470.6M | 10.6x | 34.3% |
| DCGO | DocGo Inc. | $39.8M | — | -47.7% |